Indeed, PARP inhibition has been shown to enhance the effects of radiation therapy in various cell lines and several pre-clinical tumor types including colon cancer 7, 8, prostate cancer (9), breast cancer (10), and NSCLC 9, 10, 11. This evidence concerns the gene PARP1 and non-small cell lung carcinoma.